New diabetes pill shows promise in early trial

NCT ID NCT00628212

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a new drug called teneligliptin (MP-513) in 324 Japanese adults with type 2 diabetes. Participants took one of three doses of the drug or a placebo daily for 12 weeks. The main goal was to see how well the drug lowered blood sugar levels (HbA1c) and to check for side effects. The results will help determine the right dose for larger, confirmatory studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teneligliptin (also called MP-513), a drug taken once daily to lower blood sugar
What this could lead to: If successful, this could provide a new once-daily pill option to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is an early-phase trial with only 324 participants over 12 weeks. Long-term safety and effectiveness are not yet known, and results may not apply to non-Japanese populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Study site

Takikawa-shi, Hokkaido, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.